Company intelligence / Profile preview

Transcend Biodynamics

USA

Ownership: Private
Development stage: Other

Overview

Transcend Biodynamics developed novel psychedelic compounds (notably BOL-148, a non-hallucinogenic LSD analog) for mental health, emphasizing cost-effective manufacturing and drug delivery; no clinical trial results were published prior to acquisition

Therapeutic areas: PsychiatryOther
Modalities: Small moleculePeptidePro-drugNutraceutical
Industry: Biotech

Partnerships

Major partnership/merger with BetterLife Pharma

Beyond the preview

Go deeper on Transcend Biodynamics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcend Biodynamics.

Explore the full profile